Sara A. Murphy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara A. Murphy has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Balveen Kaur
Department of Neurosurgery and Interdisciplinary Oncology, Louisiana State University Health Science Center-Louisiana, New Orleans, USA
22 shared publications - Kimberly Ann Rivera-Caraballo
Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas
20 shared publications - Bangxing Hong
Department of Pathology, Georgia Cancer Center, Augusta University, Augusta, USA
18 shared publications - Arnoneel Sinha
Augusta University 3 Center for Biotechnology and Genomic Medicine, Medical College of Georgia Augusta, Georgia
10 shared publications - Ashok Sharma
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA; Department of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA
10 shared publications - Kailash Vemuri
Augusta University 1 Department of Pathology, Georgia Cancer Center Augusta, Georgia
10 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma
Despite multimodal therapy of surgical resection, radiation, and chemotherapy, glioblastoma patients show a dismal prognosis. Protein Arginine Methyltransferase 5 (PRMT5) is overexpressed in glioblastoma, and its inhibition imparts an anti-tumor effect. Tumor cells invariably develop resistance to Temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma. However, the mechanistic role of PRMT5 in treatment-resistant glioblastoma is unknown. Patient-derived glioma stem-like cells (GSCs), treated with PRMT5 inhibitor (LLY-283) or transfected with PRMT5-target-specific siRNA, were treated with TMZ and subjected to in vitro functional and mechanistic studies. The intracranial mouse xenograft model was used to test the in vivo antitumor efficacy of combination treatment. We found that PRMT5 inhibition increased the cytotoxic effect of TMZ in GSCs. Unbiased transcriptomic profiling revealed negative enrichment of DNA damage repair pathways, with prominent suppression of the Fanconi anemia (FA) pathway. PRMT5 inhibition abrogated the TMZ-induced G2/M cell cycle arrest. Importantly, combination treatment increased the DNA double-strand breaks (γH2AX foci) and enhanced the DNA damage (comet assay). Specifically, the LLY-283 treatment blocked the FA pathway-mediated homologous recombination repair in GSCs. In vivo, the LLY-283 and TMZ combination significantly curbs tumor growth and prolongs the survival of tumor-bearing mice. Furthermore, compared to monotherapy, there was a significant reduction in the proliferation marker Ki-67, while the apoptosis marker cleaved caspase 3 and the DNA damage response marker γH2AX were upregulated. Collectively, these findings identify PRMT5 as a critical regulator of the FA pathway in glioblastoma and demonstrate that PRMT5 inhibition potentiates TMZ efficacy by disrupting FA-dependent homologous recombination repair, indicating that the combination of PRMT5 inhibition and TMZ could be a novel therapeutic strategy for glioblastoma.
- 15 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessPRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma
Despite multimodal therapy of surgical resection, radiation, and chemotherapy, glioblastoma patients show a dismal prognosis. Protein Arginine Methyltransferase 5 (PRMT5) is overexpressed in glioblastoma, and its inhibition imparts an anti-tumor effect. Tumor cells invariably develop resistance to Temozolomide (TMZ), the standard chemotherapeutic agent for glioblastoma. However, the mechanistic role of PRMT5 in treatment-resistant glioblastoma is unknown. Patient-derived glioma stem-like cells (GSCs), treated with PRMT5 inhibitor (LLY-283) or transfected with PRMT5-target-specific siRNA, were treated with TMZ and subjected to in vitro functional and mechanistic studies. The intracranial mouse xenograft model was used to test the in vivo antitumor efficacy of combination treatment. We found that PRMT5 inhibition increased the cytotoxic effect of TMZ in GSCs. Unbiased transcriptomic profiling revealed negative enrichment of DNA damage repair pathways, with prominent suppression of the Fanconi anemia (FA) pathway. PRMT5 inhibition abrogated the TMZ-induced G2/M cell cycle arrest. Importantly, combination treatment increased the DNA double-strand breaks (γH2AX foci) and enhanced the DNA damage (comet assay). Specifically, the LLY-283 treatment blocked the FA pathway-mediated homologous recombination repair in GSCs. In vivo, the LLY-283 and TMZ combination significantly curbs tumor growth and prolongs the survival of tumor-bearing mice. Furthermore, compared to monotherapy, there was a significant reduction in the proliferation marker Ki-67, while the apoptosis marker cleaved caspase 3 and the DNA damage response marker γH2AX were upregulated. Collectively, these findings identify PRMT5 as a critical regulator of the FA pathway in glioblastoma and demonstrate that PRMT5 inhibition potentiates TMZ efficacy by disrupting FA-dependent homologous recombination repair, indicating that the combination of PRMT5 inhibition and TMZ could be a novel therapeutic strategy for glioblastoma.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Cytokines in serum of tumor-naive mice
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Cytokines in serum of tumor-naive mice
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Cytokines of human PBMCs co-cultured with infected GL261N4
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Cytokines of human PBMCs co-cultured with infected GL261N4
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Figure S1 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Figure S1 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Oncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical cancer models. Clinically, the Notch ligand JAG1 was upregulated in patients with recurrent high-grade glioma treated with the oHSV CAN-3110 and correlated with poor prognosis. To better understand endogenous JAG1-mediated signaling in glioma cells and tumor-associated macrophages (TAM), we engineered a JAG1-antagonizing oHSV (OD-0J1) and interrogated its impact on cancer and myeloid cells in the TME. OD-0J1 antagonized JAG1-mediated Notch signaling and suppressed tumor growth in athymic nude and humanized mice, an effect reliant on Notch signaling in tumor cells. Kinome profiling revealed that OD-0J1 treatment suppressed CDK1, resulting in activation of the G2–M cell cycle checkpoint. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62, and autophagosome accumulation and senescence-associated β-galactosidase activity. OD-0J1–induced senescence resulted in increased production of inflammatory chemokines and damage-associated molecular patterns (DAMP), such as IL1β, HMGB1, and extracellular ATP. Coculturing macrophages with OD-0J1–infected tumor cells led to stimulation of chemotactic and proinflammatory pathways, as well as increased Fc receptor activation. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OD-0J1 treatment. Heightened EGFR activation in senescent cells was a mechanism to escape cell death, which created a unique opportunity for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the antitumor therapeutic efficacy of OD-0J1.Significance:Leveraging JAG1 antagonism in the context of oncolytic virotherapy rewires macrophage polarization within the tumor microenvironment, which has wide implications for sensitizing tumors to antibodies, senolytic agents, and BiTE therapies.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Oncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical cancer models. Clinically, the Notch ligand JAG1 was upregulated in patients with recurrent high-grade glioma treated with the oHSV CAN-3110 and correlated with poor prognosis. To better understand endogenous JAG1-mediated signaling in glioma cells and tumor-associated macrophages (TAM), we engineered a JAG1-antagonizing oHSV (OD-0J1) and interrogated its impact on cancer and myeloid cells in the TME. OD-0J1 antagonized JAG1-mediated Notch signaling and suppressed tumor growth in athymic nude and humanized mice, an effect reliant on Notch signaling in tumor cells. Kinome profiling revealed that OD-0J1 treatment suppressed CDK1, resulting in activation of the G2–M cell cycle checkpoint. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62, and autophagosome accumulation and senescence-associated β-galactosidase activity. OD-0J1–induced senescence resulted in increased production of inflammatory chemokines and damage-associated molecular patterns (DAMP), such as IL1β, HMGB1, and extracellular ATP. Coculturing macrophages with OD-0J1–infected tumor cells led to stimulation of chemotactic and proinflammatory pathways, as well as increased Fc receptor activation. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OD-0J1 treatment. Heightened EGFR activation in senescent cells was a mechanism to escape cell death, which created a unique opportunity for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the antitumor therapeutic efficacy of OD-0J1.Significance:Leveraging JAG1 antagonism in the context of oncolytic virotherapy rewires macrophage polarization within the tumor microenvironment, which has wide implications for sensitizing tumors to antibodies, senolytic agents, and BiTE therapies.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Figure S4 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Figure S4 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
RNA sequencing showing expression of alarmins and Notch signature in infected human tumor cells
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
RNA sequencing showing expression of alarmins and Notch signature in infected human tumor cells
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
GSEA pathways enriched in OD-0J1 compared to OD
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
GSEA pathways enriched in OD-0J1 compared to OD
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Figure S5 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Figure S5 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Humanized mice engraftment and human PBMC cytokine analysis
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Oncolytic HSV-1–Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis
Humanized mice engraftment and human PBMC cytokine analysis